Physician profile
Frederic D Seifer
NPI 1528013729
$78,416.50
in general payments reported to CMS, 2019-2025
29 companies · $52.55 in 2025
The $52.55 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $13K · 2021: $7,408 · 2022: $37K · 2023: $7,496 · 2024: $260 · 2025: $52.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,567 · Food and Beverage: $1,743 · Consulting Fee: $410 · Education: $89.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,566.73 |
| Food and Beverage | $1,742.88 |
| Consulting Fee | $410.00 |
| Education | $89.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $31,228.20 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Advanced Respiratory, INC | $28,406.50 | 2019-2021 | |
| Inogen, INC. | $6,916.73 | 2022-2023 | Inogen |
| Philips North America LLC | $5,718.40 | 2019-2023 | |
| Glaxosmithkline, LLC. | $1,529.54 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,063.14 | 2019-2024 | Tezspire, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.40 | 2019-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Electromed, INC. | $570.99 | 2019-2025 | Smartvest |
| Zoll Medical Corporation | $555.00 | 2020 | |
| Sunovion Pharmaceuticals INC. | $428.54 | 2019 | |
| Grifols USA, LLC | $396.50 | 2019-2024 | Prolastin-C Liquid |
| Genzyme Corporation | $343.22 | 2021-2024 | |
| Mylan Specialty L.P. | $127.80 | 2020-2023 | Yupelri |
| Amgen INC. | $103.02 | 2022-2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $97.83 | 2019-2023 | Dupixent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $82.26 | 2020-2023 | Arikayce |
| Fisher & Paykel Healthcare INC | $39.61 | 2019 | |
| Allergan, INC. | $36.79 | 2019 | |
| Circassia INC. | $29.14 | 2019 | |
| Genentech USA, INC. | $22.91 | 2019 | |
| Pharming Healthcare, INC. | $22.79 | 2024 | Ruconest |
| Pfizer INC. | $21.47 | 2021 | |
| Abbott Laboratories | $19.14 | 2023 | Freestyle Libre 2 |
| Teva Pharmaceuticals USA, INC. | $16.78 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.29 | 2022 | |
| Monaghan Medical Corporation | $12.67 | 2019 | |
| Merck Sharp & Dohme LLC | $11.84 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederic Seifer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.